NTHI (NeOnc Technologies Holdings) Short Interest


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NTHI vs GUTS, PEPG, ENGN: Short Interest Comparison

For the Biotechnology subindustry, NeOnc Technologies Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeOnc Technologies Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where NeOnc Technologies Holdings's Short Interest falls into.


NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price